Motoneuron‐specific loss of VAChT mimics neuromuscular defects seen in congenital myasthenic syndrome
Open Access
- 17 March 2021
- journal article
- research article
- Published by Wiley in The FEBS Journal
- Vol. 288 (18) , 5331-5349
Abstract
Motoneurons (MNs) control muscle activity by releasing the neurotransmitter acetylcholine (ACh) at the level of neuromuscular junctions. ACh is packaged into synaptic vesicles by the vesicular ACh transporter (VAChT), and disruptions in its release can impair muscle contraction, as seen in congenital myasthenic syndromes (CMS). Recently, VAChT gene mutations were identified in humans displaying varying degrees of myasthenia. Moreover, mice with a global deficiency in VAChT expression display several characteristics of CMS. Despite these findings, little is known about how a long‐term decrease in VAChT expression in vivo affects MNs structure and function. Using Cre‐loxP technology, we generated a mouse model where VAChT is deleted in select groups of MNs (mnVAChT‐KD). Molecular analysis revealed that the VAChT deletion was specific to MNs and affected approximately 50% of its population in the brainstem and spinal cord, with alpha‐MNs primarily targeted (70% in spinal cord). Within each animal, the cell body area of VAChT‐deleted MNs was significantly smaller compared to MNs with VAChT preserved. Likewise, muscles innervated by VAChT‐deleted MNs showed atrophy while muscles innervated by VAChT‐containing neurons appeared normal. In addition, mnVAChT KD mice had decreased muscle strength, were hypoactive, leaner and exhibited kyphosis. This neuromuscular dysfunction was evident at 2 months of age and became progressively worse by 6 months. Treatment of mutants with a cholinesterase inhibitor was able to improve some of the motor deficits. As these observations mimic what is seen in CMS, this new line could be valuable for assessing the efficacy of potential CMS drugs.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (401071/2014‐6)
This publication has 56 references indexed in Scilit:
- Reduced Expression of the Vesicular Acetylcholine Transporter and Neurotransmitter Content Affects Synaptic Vesicle Distribution and Shape in Mouse Neuromuscular JunctionPLOS ONE, 2013
- Rapid Determination of Myosin Heavy Chain Expression in Rat, Mouse, and Human Skeletal Muscle Using Multicolor Immunofluorescence AnalysisPLOS ONE, 2012
- Elimination of the Vesicular Acetylcholine Transporter in the Striatum Reveals Regulation of Behaviour by Cholinergic-Glutamatergic Co-TransmissionPLOS Biology, 2011
- Novel Strains of Mice Deficient for the Vesicular Acetylcholine Transporter: Insights on Transcriptional Regulation and Control of Locomotor BehaviorPLOS ONE, 2011
- Quantal release of acetylcholine in mice with reduced levels of the vesicular acetylcholine transporterJournal of Neurochemistry, 2010
- Dysautonomia Due to Reduced Cholinergic Neurotransmission Causes Cardiac Remodeling and Heart FailureMolecular and Cellular Biology, 2010
- A robust and high-throughput Cre reporting and characterization system for the whole mouse brainNature Neuroscience, 2009
- The Vesicular Acetylcholine Transporter Is Required for Neuromuscular Development and FunctionMolecular and Cellular Biology, 2009
- Gamma and alpha motor neurons distinguished by expression of transcription factor Err3Proceedings of the National Academy of Sciences, 2009
- Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase InhibitorThe Japanese Journal of Pharmacology, 2002